SCHEMBL4340593

SCHEMBL4340593

CC(C)(C)OC(=O)Nc1ccc(Nc2nc(Cl)ncc2Cl)cc1CCc1cncc(NC(=O)O)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17B O94768 1/20 0.41
STK17A Q9UEE5 1/20 0.41
BCL6 P41182 1/20 0.38
P2RX3 P56373 4/20 0.37
SYK P43405 2/20 0.36
P2RX7 Q99572 1/20 0.34
MET P08581 1/20 0.34
CDK1 P06493 1/20 0.34
EGFR P00533 3/20 0.34
ALK Q9UM73 2/20 0.34
MAPK3 P27361 2/20 0.34
AURKB Q96GD4 1/20 0.34
SRC P12931 1/20 0.34
MAPKAPK2 P49137 1/20 0.33
CCNK O75909 1/20 0.33
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33
CCND3 P30281 1/20 0.33
CDK9 P50750 1/20 0.33
CDK6 Q00534 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13622748 0.96 STK17B (0.43) STK17BSTK17ABCL6P2RX3SYK
SCHEMBL1024947 0.94 P2RX3 (0.37) STK17BSTK17AP2RX3SYKP2RX7
SCHEMBL1024939 0.92 SYK (0.42) STK17BSTK17AP2RX3SYKCDK1
SCHEMBL1026903 0.90 STK17B (0.41) STK17BSTK17ABCL6P2RX3SYK
SCHEMBL13623074 0.90 P2RX3 (0.38) STK17BSTK17AP2RX3SYKCDK1
SCHEMBL2523055 0.89 STK17B (0.44) STK17BSTK17AP2RX3P2RX7EGFR
SCHEMBL13623071 0.88 SYK (0.46) STK17BSTK17AP2RX3SYKCDK1
SCHEMBL1028573 0.88 STK17B (0.39) STK17BSTK17ABCL6P2RX3SYK
SCHEMBL13622745 0.86 SYK (0.43) STK17BSTK17ABCL6SYKP2RX7
SCHEMBL12209872 0.85 STK17B (0.46) STK17BSTK17AP2RX3EGFRMAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK STK17B 139/4885STK17A 74/4885BCL6 392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.